Identification of peptides from autoantigens GAD65 and IA-2 that bind to HLA class II molecules predisposing to or protecting from type 1 diabetes.

E Harfouch-Hammoud, T Walk, H Otto, G Jung… - Diabetes, 1999 - Am Diabetes Assoc
E Harfouch-Hammoud, T Walk, H Otto, G Jung, JF Bach, PM van Endert, S Caillat-Zucman
Diabetes, 1999Am Diabetes Assoc
Type 1 diabetes is a T-cell-mediated disease in which presentation of autoantigens to CD4+
T-cells is thought to play a crucial role. Polymorphism of HLA class II genes accounts for
50% of the genetic risk of contracting type 1 diabetes. HLA-DQ and-DR molecules
predisposing to or protecting from type 1 diabetes have been identified, but the molecular
basis controlling these associations is as yet undefined. Apart from distinct thymic selection
of autoreactive T-cells by susceptible and protective HLA molecules, exclusive presentation …
Type 1 diabetes is a T-cell-mediated disease in which presentation of autoantigens to CD4+ T-cells is thought to play a crucial role. Polymorphism of HLA class II genes accounts for 50% of the genetic risk of contracting type 1 diabetes. HLA-DQ and -DR molecules predisposing to or protecting from type 1 diabetes have been identified, but the molecular basis controlling these associations is as yet undefined. Apart from distinct thymic selection of autoreactive T-cells by susceptible and protective HLA molecules, exclusive presentation of autoantigenic peptides by type 1 diabetes-predisposing HLA molecules or, alternatively, induction of regulatory T-cells by protective alleles are potential mechanisms for modification of type 1 diabetes risk by HLA polymorphism. As a first step in exploring the role of HLA molecules in autoantigen-specific cellular responses in type 1 diabetes, we have screened peptides covering the sequence of two major autoantigens targeted by humoral and cellular immune responses, GAD65 and islet associated-2 (IA-2), for binding to class II molecules. We developed a sensitive novel competition binding assay allowing us to measure peptide binding on intact cells to 10 HLA-DR and 4 HLA-DQ molecules. For all tested alleles, multiple peptides binding with high affinity were identified. We report clustering of binding peptides in the COOH-terminal regions of GAD65 and IA-2, as well as highly promiscuous binding patterns of some peptides. Our results demonstrate that most peptides derived from the GAD and IA-2 autoantigens can bind to both type 1 diabetes-predisposing and type 1 diabetes-protective HLA molecules, although some exceptions were observed. The binding inventory presented here for GAD and IA-2 peptides can be useful for mapping natural epitopes and predicting peptide-specific responses induced by preventive immunization.
Am Diabetes Assoc